Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | 246-251 |
| Numero di pagine | 6 |
| Rivista | EUROPEAN JOURNAL OF NEUROLOGY |
| Volume | 18 |
| Stato di pubblicazione | Published - 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Neurology
- Clinical Neurology
Cita questo
Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome. / Mangano, Salvatore; D'Aniello; Balestri; Parisi; Zamponi; Spalice; Fels; Veggiotti; Pascotto; Franzoni; Curatolo; Grosso; Coppola; Verrotti, Alberto; Habetswallner.
In: EUROPEAN JOURNAL OF NEUROLOGY, Vol. 18, 2011, pag. 246-251.Risultato della ricerca: Article
}
TY - JOUR
T1 - Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome.
AU - Mangano, Salvatore
AU - D'Aniello, null
AU - Balestri, null
AU - Parisi, null
AU - Zamponi, null
AU - Spalice, null
AU - Fels, null
AU - Veggiotti, null
AU - Pascotto, null
AU - Franzoni, null
AU - Curatolo, null
AU - Grosso, null
AU - Coppola, null
AU - Verrotti, Alberto
AU - Habetswallner, null
PY - 2011
Y1 - 2011
N2 - Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ‡50% seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6%).Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5%) and increased in five patients (13.1%). Elevenpatients (28.9%) reported adverse side effects. Vomiting was reported in five patients(13.1%); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.
AB - Background: To report on the first multicenter Italian experience with rufinamide asadjunctive drug in children, adolescents and young adults with refractory childhoodonsetepileptic encephalopathies other than Lennox–Gastaut syndrome.Methods: Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractoryepileptic encephalopathies other than Lennox–Gastaut syndrome, were treated withrufinamide as adjunctive drug for a mean period of 11.4 months (range 3–26 months).Results: Fifteen of 38 patients (39.5%) had a ‡50% seizure reduction in countableseizures. Complete seizure freedom was achieved in one of these patients (2.6%).Three patients (7.9%) had a 25–49% seizure reduction, whilst seizure frequencyremained unchanged in 15 (39.5%) and increased in five patients (13.1%). Elevenpatients (28.9%) reported adverse side effects. Vomiting was reported in five patients(13.1%); drowsiness, decreased appetite and irritability with migraine manifested inother four patients. They were transient and mild in all cases.Conclusion: Rufinamide may be an effective and well-tolerated adjunctive drug forthe treatment of refractory childhood-onset epileptic encephalopathies other thanLennox–Gastaut syndrome. Rufinamide was most effective in patients with dropattacksand (bi)frontal spike–wave discharges.
KW - epileptic encephalopathies-childhood
KW - refractory seizures
KW - rufinamide
UR - http://hdl.handle.net/10447/50698
M3 - Article
VL - 18
SP - 246
EP - 251
JO - EUROPEAN JOURNAL OF NEUROLOGY
JF - EUROPEAN JOURNAL OF NEUROLOGY
SN - 1351-5101
ER -